Patterns of remission in pemphigus vulgaris

被引:158
作者
Herbst, A [1 ]
Bystryn, JC [1 ]
机构
[1] NYU, Med Ctr, Ronald O Perelman Dept Dermatol, New York, NY 10016 USA
关键词
D O I
10.1016/S0190-9622(00)90213-5
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The incidence of remissions in pemphigus is unclear because these are usually reported at a single point in the evolution of the disease. Thus it is uncertain whether treatment simply suppresses the manifestations of the disease and consequently must be continuously administered, or induces complete and long-lasting remissions that permit therapy to be discontinued. Objective: To answer this question, we investigated the incidence of remission in a long-term longitudinal study Methods: The induction of complete and long-lasting remissions (lesion free with no systemic therapy for at least 6 months) was studied in 40 patients with pemphigus vulgaris treated conventionally and followed up for an average of 7.7 years by the same investigator. Results: Five (5%) of the patients died of the disease. Complete and long-lasting remissions were induced in 25%, 50%, and 75% of patients 2, 5, and 10 years, respectively, after diagnosis. Most of the remaining patients were in partial remission or had mild disease controlled with a small dose of steroids. The course of the disease followed different patterns, with some patients rapidly entering complete and long-lasting remissions, whereas others never entered into a complete remission. The induction of complete remission was related to the initial severity and extent of disease and to ear ly response to treatment. Conclusion: It is possible to eventually induce complete and durable remissions in most patients with pemphigus that permit systemic therapy to be safely discontinued without a flare in disease activity. The proportion of patients in whom this can be achieved increases steadily with time, and therapy can be discontinued in approximately 75% of patients after 10 years.
引用
收藏
页码:422 / 427
页数:6
相关论文
共 11 条
[1]   TREATMENT OF 9 CASES OF PEMPHIGUS VULGARIS WITH CYCLOSPORINE [J].
BARTHELEMY, H ;
FRAPPAZ, A ;
CAMBAZARD, F ;
MAUDUIT, G ;
ROUCHOUSE, B ;
KANITAKIS, J ;
SOUTEYRAND, P ;
CLAUDY, AL ;
THIVOLET, J .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1988, 18 (06) :1262-1266
[2]   ADJUVANT THERAPY OF PEMPHIGUS [J].
BYSTRYN, JC .
ARCHIVES OF DERMATOLOGY, 1984, 120 (07) :941-951
[3]  
BYSTRYN JC, 1988, SEMIN DERMATOL, V7, P186
[4]   The adjuvant therapy of pemphigus - An update [J].
Bystryn, JC ;
Steinman, NM .
ARCHIVES OF DERMATOLOGY, 1996, 132 (02) :203-212
[5]   SUCCESSFUL USE OF CYCLOPHOSPHAMIDE AND PREDNISONE FOR INITIAL TREATMENT OF PEMPHIGUS VULGARIS [J].
FELLNER, MJ ;
KATZ, JM ;
MCCABE, JB .
ARCHIVES OF DERMATOLOGY, 1978, 114 (06) :889-894
[6]  
Kanwar Amrinder J., 1994, Journal of Dermatology (Tokyo), V21, P655, DOI 10.1111/j.1346-8138.1994.tb01811.x
[7]   THE EFFICACY OF COMBINED TREATMENT WITH PREDNISONE AND CYCLOSPORINE IN PATIENTS WITH PEMPHIGUS - PRELIMINARY-STUDY [J].
LAPIDOTH, M ;
DAVID, M ;
BENAMITAI, D ;
KATZENELSON, V ;
LUSTIG, S ;
SANDBANK, M .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1994, 30 (05) :752-757
[8]  
MOURELLOU O, 1995, BRIT J DERMATOL, V133, P83
[9]  
PIAMPHONGSANT T, 1979, Journal of Dermatology (Tokyo), V6, P359
[10]  
SURRINDER K, 1990, INT J DERMATOL, V29, P363